Literature DB >> 14672626

Overweight and obesity, hepatic steatosis, and progression of chronic hepatitis C: a retrospective study on a large cohort of patients in the United States.

Ke-Qin Hu1, Namgyal L Kyulo, Eric Esrailian, Kevin Thompson, Resa Chase, Donald J Hillebrand, Bruce A Runyon.   

Abstract

BACKGROUND: Hepatic steatosis has been associated with chronic hepatitis C (CHC), but its prevalence, risk factors, and clinical significance remain to be determined. AIMS: The present study determined the frequency of, and risk factors for hepatic steatosis and its association with activity and progression of CHC in a large cohort of U.S. patients.
METHODS: This is a retrospective study that utilized systematic chart review and statistical analyzes to investigate 324 U.S. patients with CHC from a university medical center and a regional VA medical center.
RESULTS: The frequency of hepatic steatosis was 66.0%. We demonstrated that not only being obese, but also overweight (i.e. body mass index > or =25 kg/m(2)) was independently associated with hepatic steatosis. In our cohort of patients with CHC, hepatic steatosis, especially grade II/III steatosis, was significantly associated with elevated aspartate aminotransferase at entry, persistently elevated alanine aminotransferase, and stage III/IV fibrosis. Grade II/III steatosis, was significantly associated with a higher histology activity index as well. Multivariate analysis indicated that steatosis, especially grade II/III steatosis, was independently associated with stage III/IV fibrosis.
CONCLUSIONS: Being overweight/obese serves as an independent risk factor for hepatic steatosis in U.S. patients with CHC. Steatosis accelerates activity and progression of CHC, and is independently associated with stage III/IV hepatic fibrosis in these patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14672626     DOI: 10.1016/s0168-8278(03)00479-3

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  31 in total

1.  Digital quantification is more precise than traditional semiquantitation of hepatic steatosis: correlation with fibrosis in 220 treatment-naïve patients with chronic hepatitis C.

Authors:  Sekou R Rawlins; Ola El-Zammar; J Michael Zinkievich; Nancy Newman; Robert A Levine
Journal:  Dig Dis Sci       Date:  2010-05-12       Impact factor: 3.199

2.  Influence of body mass index on outcome of pediatric chronic hepatitis C virus infection.

Authors:  Aymin Delgado-Borrego; David Healey; Betania Negre; Marielle Christofi; Sabina Sabharwal; David A Ludwig; Raymond T Chung; Maureen M Jonas
Journal:  J Pediatr Gastroenterol Nutr       Date:  2010-08       Impact factor: 2.839

3.  Clinical implications of hepatic steatosis in patients with chronic hepatitis C: a multicenter study of U.S. veterans.

Authors:  Ke-Qin Hu; Sue L Currie; Hui Shen; Ramsey C Cheung; Samuel B Ho; Edmund J Bini; John D McCracken; Tim Morgan; Norbert Bräu; Warren N Schmidt; Lennox Jeffers; Teresa L Wright
Journal:  Dig Dis Sci       Date:  2007-01-17       Impact factor: 3.199

4.  Test-retest repeatability of MR elastography for noninvasive liver fibrosis assessment in hepatitis C.

Authors:  Norah J Shire; Meng Yin; Jun Chen; Radha A Railkar; Sabrina Fox-Bosetti; Stephanie M Johnson; Chan R Beals; Bernard J Dardzinski; Schuyler O Sanderson; Jayant A Talwalkar; Richard L Ehman
Journal:  J Magn Reson Imaging       Date:  2011-07-12       Impact factor: 4.813

5.  Human immunodeficiency virus-infected and uninfected adults with non-genotype 3 hepatitis C virus have less hepatic steatosis than adults with neither infection.

Authors:  Jennifer C Price; Yifei Ma; Rebecca Scherzer; Natalie Korn; Kyle Tillinghast; Marion G Peters; Susan M Noworolski; Phyllis C Tien
Journal:  Hepatology       Date:  2017-02-03       Impact factor: 17.425

6.  Weight-related effects on disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial.

Authors:  James E Everhart; Anna S Lok; Hae-Young Kim; Timothy R Morgan; Karen L Lindsay; Raymond T Chung; Herbert L Bonkovsky; Marc G Ghany
Journal:  Gastroenterology       Date:  2009-05-13       Impact factor: 22.682

Review 7.  Managing chronic hepatitis C in the difficult-to-treat patient.

Authors:  Nyingi Kemmer; Guy W Neff
Journal:  Liver Int       Date:  2007-12       Impact factor: 5.828

Review 8.  Pathogenesis and significance of hepatitis C virus steatosis: an update on survival strategy of a successful pathogen.

Authors:  Amedeo Lonardo; Luigi Elio Adinolfi; Luciano Restivo; Stefano Ballestri; Dante Romagnoli; Enrica Baldelli; Fabio Nascimbeni; Paola Loria
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

9.  Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C.

Authors:  Marc G Ghany; Anna S F Lok; James E Everhart; Gregory T Everson; William M Lee; Teresa M Curto; Elizabeth C Wright; Anne M Stoddard; Richard K Sterling; Adrian M Di Bisceglie; Herbert L Bonkovsky; Chihiro Morishima; Timothy R Morgan; Jules L Dienstag
Journal:  Gastroenterology       Date:  2009-09-18       Impact factor: 22.682

Review 10.  Dysmetabolic changes associated with HCV: a distinct syndrome?

Authors:  Amedeo Lonardo; Paola Loria; Nicola Carulli
Journal:  Intern Emerg Med       Date:  2008-02-15       Impact factor: 3.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.